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ABSTRACT 
 
 Structural and Functional Studies of Mycothiol Biosynthesis Precursor Enzyme in 
Mycobacterium tuberculosis. 
(August 2011) 
Wan Wen Zhu, B.S., Polytechnic University 
Chair of Advisory Committee: Dr. James C. Sacchettini 
 
 MshA is a glycosyltransferase that synthesizes the precursor of mycothiol, a low-
molecular-weight thiol found exclusively in Actinomycetes, including the virulent 
pathogen Mycobacterium tuberculosis (Mtb).  The structure of MshA from Mtb (herein 
coined as TbMshA) and its complex with uridine diphosphate N-acetyl-glucosamine 
(UDP-GlcNAc) have been solved to resolutions of 2.32 Å and 2.89 Å respectively.  Both 
structures form two monomers in the asymmetric unit cell and exhibit typical β/α/β 
Rossmann folds.  Upon binding of UDP-GlcNAc, the C-terminal domain of TbMshA 
undergoes conformational changes in order to interact with UDP-GlcNAc at the binding 
site.  In addition, ligand-bound TbMshA structure enables the identification of critical 
residues for enzymatic interactions, especially the residue Glu-353 (E353) at the active 
site that is believed to serve as a nucleophile in the sugar transfer of TbMshA.  In order 
to verify this, a mutant of TbMshA with a single amino acid mutation from glutamate to 
glutamine at residue 353 is generated.  The mutant (E353Q) has shown reduced enzyme 
activity by more than four-fold compared to the wild-type TbMshA (Vmax for wild-type 
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is 0.17 ± 0.02 M sec-1, whereas Vmax for E353Q is 0.04 ± 0.01 M sec-1).  The kcat/Km 
for wild-type TbMshA (3.5 ± 1.1 * 103 M-1 sec-1) is an order of magnitude higher than 
that of the mutant (0.3 ± 0.1 * 103 M-1 sec-1), indicating the catalytic efficiency is greatly 
suppressed by the mutation.  Mass spectrometry data also reveals that E353Q is unable 
to form the product of the reaction catalyzed by the wild-type TbMshA.  These findings 
suggest the important role of Glu-353 in the structure and activity of TbMshA.   
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NOMENCLATURE 
 
CgMshA  MshA from Corynebacterium glutamicum 
ESI   Electrospray Ionization 
E353Q   a mutant of MshA in Mtb generated in this thesis  
GlcNAc  N-acetyl-glucosamine 
GlcNAc-Ins-P  N-acetyl-glucosamine-inositol-phosphate 
I-1-P   1L-myo-inositol-1-phosphate 
LDH   lactate dehydrogenase 
MDR   multiple-drug resistance 
MSH   mycothiol 
Mtb   Mycobacterium tuberculosis 
NAD+   nicotinamide adenine dinucleotide 
NADH   nicotinamide adenine dinucleotide reduced  
PK   pyruvate kinase   
PO4   phosphate 
TB   Tuberculosis 
TbMshA  MshA from Mycobacterium tuberculosis 
UDP   uridine diphosphate 
UDP-GlcNAc  uridine diphosphate N-acetyl-glucosamine 
WT   wild-type 
XDR   extensive-drug resistance 
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1. INTRODUCTION 
  
Tuberculosis (TB) is a notorious infectious disease that is affecting nearly one-
third of the world’s population to date (1).  Mycobacterium tuberculosis (Mtb) is the 
virulent agent that is responsible for the spread of TB.  New cases of TB infection 
increase daily, especially in poor hygiene and HIV-prevalent countries (1).  The 
occurrence of multiple-drug resistant (MDR) and extensive-drug resistant (XDR) TB 
also raise the concern of current anti-tubercular regimen (2).  In order to improve anti-
tubercular treatment at the clinical side, much effort is being paid to understand this 
deadly pathogen’s own defensive mechanisms. 
One of the many biosynthetic pathways known for Mtb is the mycothiol 
biosynthesis.  Mycothiol (MSH) or 2-(N-acetylcysteinyl) amido-2-deoxy-α-D-
glucopyranosyl-(11)-myo-inositol (Figure 1) is the major low-molecular weight thiol 
found in most Actinomycetes; it is a class of gram-positive bacteria including the virulent 
pathogen Mycobacterium tuberculosis (Mtb) (3). 
 
Figure 1. The chemical structure of mycothiol (MSH). 
____________ 
This thesis follows the style of The Journal of Biological Chemistry. 
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Bearing the similar antioxidant nature as glutathione (4,5), mycothiol has been 
found to be conditionally essential for growth in Mtb (6), most importantly, mycothiol 
has not been found in eukaryotes, rendering the enzymes involved in the biosynthetic 
pathway of mycothiol valuable anti-tuberculosis drug targets. 
There are four enzymes that have been identified in mycothiol biosynthesis 
(Figure 2): 
 
 
Figure 2. The biosynthetic pathway of mycothiol (7). 
 
 
MshA is a glycosyltransferase proposed to catalyze the reaction of uridine 
diphosphate N-acetyl-glucosamine (UDP-GlcNAc) with 1L-myo-inositol-1-phosphate 
(I-1-P) to generate GlcNac-(α1,3)-1L-Ins-1-P (8) or known as N-acetyl-glucosamine-
inositol-phosphate (GlcNAc-Ins-P, in this thesis), which is then deacetylated by MshB to 
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generate GlcN-Ins (9).  MshC helps to ligate the GlcN-Ins with cysteine utilizing the 
hydrolysis power of ATP to generate Cys-GlcN-Ins (10), and finally MshD catalyzes the 
acetylation of Cys-GlcN-Ins using acetyl-CoA to produce mycothiol (11). 
MshA has been identified as the enzyme that catalyzes the precursor reaction in 
the mycothiol pathway.  It has been considered essential for mycothiol biosynthesis 
through genetic knockout studies (8).  Deletions of MshA alleles cause defective 
production of mycothiol, and recent report show that mycothiol biosynthesis even has 
implications in drug resistance TB; an increased susceptibility to ethionamide (second-
line TB drug) resistance in Mtb with mutations in the MshA gene is observed (12). 
In order to understand MshA in mycothiol biosynthesis before investigating its 
implication in Mtb drug resistance, the biochemistry of such mechanism should be 
elucidated.  Although this initial step in the mycothiol biosynthetic pathway has been 
well characterized in the past decade, and the proposed substrates are defined (13), a 
crystal structure of this enzyme has not yet been determined.  Herein, two crystal 
structures are solved for MshA from Mtb, the native enzyme with no ligand bound, and a 
UDP-GlcNAc bound MshA complex, in which the latter structure locates the substrate 
binding cavity and provides hints for this precursor reaction in the biosynthesis of 
mycothiol.    
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2. MATERIALS AND METHODS 
 
2.1 Cloning, expression and purification of TbMshA 
The original MshA gene (rv0486, 480 amino acids in full length) from 
Mycobacterium tuberculosis genome (H37Rv), coined TbMshA, was amplified via 
Polymerase Chain Reaction (PCR) using FailsafeTM kit (Epicentre) with primers 5’-GGC 
CCG AAG CTT TCA CGC GCC CAC CCC GC -3’ (forward) and 5’- CCG CGG CAT 
ATG GCA GGT GTG CGG CAC GAT GAC G-3’ (reverse).  The amplified TbMshA 
gene was cloned into kanamycin-resistant pET28b(+) vector (Novagen) with restriction 
sites of Nde1 and HindIII, containing a N-terminal 6X His-tag and a tobacco etch virus 
(TEV) cleavage sequence.  The TbMshA-pET28b(+) plasmid was transformed in 
BL21DE3 (Invitrogen) expression system.  A single colony was picked and inoculated 
into a 5-ml starter culture (with 50 g/ml kanamycin), which would be used to inoculate 
large Luria-Broth (LB) media (2 x 2-liter) and the cell culture (with kanamycin resistant) 
were grown at 37oC with shaking at 200 revolutions per minute (RPM) until optical 
density at 600 nm (OD600) reached ~ 0.8-0.9.  Cells were induced using isopropyl β-D-1-
thiogalactopyranoside (IPTG) and grown at 18oC for 20-24 hours.  Cells were then 
harvested by centrifugation at 4000 RPM for 30 minutes.  Cell pellets were resuspended 
in 2-3 times of pellet volume of lysis buffer (20 mM Tris, pH 8.5, 500 mM sodium 
chloride (NaCl), 20% glycerol, 5 mM imidazole) at 4oC.  Aliquots of DNase (final 
concentration of 20 g/ml) and ethylenediaminetetraacetic acid (EDTA)-free protease 
inhibitors (CalbioChem) solution were added into the cell resuspension just before 
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lyzing cells.  Cell lysis was done using French Press at 1200 pounds per square inch 
(PSI).  Cell lysate was obtained after ultracentrifugation at 15,000 RMP for 50 minutes.  
Clear lysate (after filtration using 0.22 micron filter from Fischer Scientific) was loaded 
onto pre-packed Ni-NTA nickel column (GE Healthcare).  The column was washed 
thoroughly with buffer A (20 mM Tris, pH 8.5, 500 mM NaCl, 20% glycerol, 5 mM 
imidazole, 2 mM -mercaptoethanol), and eluted with buffer B (buffer A + 500 mM 
imidazole) in gradient mode (50-500 mM of imidazole) using fast protein liquid 
chromatography (FPLC from AktaTM).  Pure fractions of proteins were eluted at around 
150 mM imidazole and pooled for dialysis at 4oC to get rid of excessive imidazole and 
salt.  Dialyzed fractions were concentrated down via ultrafiltration (Amicon) to a 
concentration of ~ 5-9 mg/ml and store at 4oC (if set up crystal plates immediately, 
otherwise flash-freeze at -80oC).  Removal of N-terminal 6X His-tag was done by 
incubating the concentrated protein with TEV enzyme (10:1 protein to enzyme in molar 
ratio) in 20 mM Tris, pH 8.5, 20% glycerol and 100 mM NaCl, and 1 mM dithiothreitol 
(DTT) at 16oC for overnight (12 hours).  
 
2.2 Crystallization and structure determination of TbMshA  
Crystallizations of both apo and ligand-bound TbMshA were set up in a 24-well 
sitting drop fashion under silicon oil (Hampton Research) at 16oC.  Apo TbMshA 
crystals were obtained overnight with rhombohedral morphology in 100 mM Tris, pH 
8.5, and 2.5 M ammonium phosphate.  Ligand-bound TbMshA crystals were obtained 
overnight with diamond-shape (Figure 3) in 100 mM Tris, pH 8.5, 15% polyethylene 
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glycol (PEG) 4000, and 10 mM uridine diphosphate glucosamine (UDP-GlcNAc) 
sodium salt (Sigma).   
 
 
Figure 3. A picture of the UDP-GlcNAc bound TbMshA crystal. 
 
Apo crystal was soaked in crystal condition (mother liquor) with 20% glycerol 
(final concentration) before mounting in liquid nitrogen at 120 degree Kelvin (K) for 
data collection.  UDP-GlcNAc co-crystallized (ligand-bound) TbMshA crystals were 
soaked in mother liquor with 25% PEG 400 prior to cryo mounting.  Apo TbMshA data 
(Figure 4) were collected at Advanced Photon Source 23ID-D (Argonne National 
Laboratory).  The initial UDP-GlcNAc bound TbMshA data were collected at 23ID-B 
and also at home source (soaked with 10 mM myo-inositol and 10 mM ammonium 
phosphate, final concentration) from Bruker with CCD image detector.   
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Figure 4. X-ray diffraction of apo TbMshA crystal. 
 
Both apo and ligand-bound data sets were processed using HKL2000.  The space 
group of apo TbMshA protein was determined to be P21212 with unit cell dimensions of 
a = 159.3 Å, b = 56.6 Å, c = 106.6 Å,  =  =  = 90o.  And the space group of ligand-
bound TbMshA was determined to be P41212 with unit cell dimensions of a = 123.6 Å, b 
= 123.6 Å, c = 154.0 Å,  =  =  = 90o.  Both crystals have two monomers in the 
asymmetric unit assumed a solvent content of 50%.  The structure of UDP-GlcNAc 
bound TbMshA was determined using molecular replacement (CCP4 molprep) with the 
solved ligand-bound CgMshA (Protein Data Bank or PDB code: 3c4v) as an input 
phasing model.  The native TbMshA structure was solved by using the C-terminal 
domain of the ligand-bound TbMshA as the initial searching model, and then used the 
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searched solution as a fixed searching model while finding another solution using the N-
terminal domain as a second search model in CCP4 molrep.  Model building was done 
using COOT for both structures and refined using Phenix.  For the UDP-GlcNAc bound 
TbMshA structure, the ligand PDB was generated using PRODRG server, molecular 
constraints were calculated using Phenix eLBOW.builder and refined into the structure 
using Phenix refine.  The first 42 residues and the last 29 residues of both TbMshA 
structures lack electron density after refinement maybe due to high disorderness or 
flexibilities at the termini. 
 
2.3 Construction of TbMshA mutant (E353Q) 
A single amino acid mutation was introduced for TbMshA at residue 353 (a 
glutamate) via the site-directed mutagenesis kit from Stratagene.  In order to construct 
this mutant, the original TbMshA gene (Rv0486) was PCR amplified using primers 5’- 
GCG GTG CCG AGC TAC TCC CAG TCG TTC GGC CTG GTT GC -3’ (forward) 
and 5’- GC AAC CAG GCC GAA CGA CTG GGA GTA GCT CGG CAC CGC-3’ 
(reverse), in which the underscored codon was the site where the mutation was 
introduced.  This single amino acid mutation, Q  E, also corresponded to a single 
nucleotide mutation, G  C (GAG => glutamic acid, CAG => glutamine).  The 
amplified mutant gene (namely E353Q) was cloned into kanamycin-resistant pET28b(+) 
vector (Novagen) with restriction sites of Nde1 and HindIII, containing a N-terminal 6X 
His-tag and a TEV cleavage sequence.  E353Q-pET28b(+) was transformed into 
BL21DE3 (Invitrogen) expression system and expressed in the same fashion as that of 
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original TbMshA gene (or wild-type gene).  The mutant TbMshA protein, E353Q, was 
also purified following the same protocol mentioned previously (Section 2.1) for the 
wild-type TbMshA.      
 
2.4 Measurement of enzymatic activity for TbMshA 
The TbMshA enzyme kinetics assay was carried out in a coupled enzyme assay 
by monitoring the production of uridine diphosphate (UDP) at 340 nm (14).  The 
standard assay condition contained (final concentration): 200 nM enzyme, 20 mM Tris, 
pH 8.0, 500 M NADH, 500 M phosphoenol pyruvate (PEP), 10 mM magnesium 
chloride (MgCl2), 8 units of pyruvate kinase (PK in 50% glycerol suspension, from 
Sigma) and 10 units of lactate dehydrogenase (LDH in 50% glycerol suspension, from 
Sigma).  The final reaction mixture (50 l) was allowed to equilibrate for 2 minutes 
before adding the substrates to start the reaction.  Reactions were monitored using 96-
well flat bottom transparent assay plate (from Greiner) and the results were recorded by 
96-well plate reader (Polarstar Omega, BMG labtech).    
Donor kinetics was performed for both wild-type and mutant TbMshA, while 
holding the acceptor substrate (I-1-P) at constant/saturating concentration (2 mM).  The 
concentration of donor substrate (UDP-GlcNAc) varied from 4 mM (final concentration) 
to 0 mM via serial dilution in the final reaction mixture.  Each final reaction mixture 
contained 200 nM of enzyme, 500 M of NADH, 500 M of PEP, 1 mg/ml of bovine 
serum albumin (BSA), 10 mM of MgCl2, 8 units of PK and 10 units of lactate LDH, 2 
mM of I-1-P, and 20 mM Tris, pH 8.0.  The total reaction mixture (50 l) was incubated 
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for 2 minutes before adding UDP-GlcNAc.  Ten measurements with respect to ten serial 
dilutions were taken at 340 nm (using a 96-well plate reader from Polarstar Omega, 
BMG labtech) for a period of thirty minutes.  The linear portion of the kinetics was taken 
to calculate the reaction velocity, and it was plotted against donor substrate 
concentration at saturating acceptor concentration.         
Acceptor kinetics was performed for both wild-type and mutant TbMshA, while 
holding the donor substrate (UDP-GlcNAc) at constant/saturating concentration (at 4 
mM).  The concentration of acceptor substrate (I-1-P) varied from 2 mM (final 
concentration) to 0 mM via serial dilution in the final reaction mixture.  Each final 
reaction mixture contained 200 nM of enzyme, 500  of NADH, 500 M of PEP, 1 
mg/ml of bovine serum albumin (BSA), 10 mM of MgCl2, 8 units of PK and 10 units of 
LDH, 4 mM of UDP-GlcNAc, and 20 mM Tris, pH 8.0.  The total reaction mixture was 
incubated for 2 minutes before adding I-1-P.  Ten measurements with respect to ten 
serial dilutions were taken at 340 nm (using a 96-well plate reader from Polarstar 
Omega, BMG labtech) for a period of thirty minutes.  The linear portion of the kinetics 
was taken to calculate the reaction velocity, and it was plotted against acceptor substrate 
concentration at saturating donor concentration. 
 
2.5 Mass spectrometry experiment for TbMshA  
Mass spectrometry experiments for TbMshA and its mutant, E353Q, were done 
in the Laboratory for Biological Mass Spectrometry in the Department of Chemistry.  
Sample analytes from TbMshA and E353Q were extracted from in vitro reaction in 
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which 5 l of enzyme (from stock concentration) was added into a 100 l reaction buffer 
containing 20 mM Tris, pH 8.0, 5 mM (final concentration) of UDP-GlcNAc and I-1-P, 
incubated at room temperature for 2 hours before storing at 4oC for overnight.  Control 
sample analytes contained either the UDP-GlcNAc or I-1-P, dissolved in distilled water, 
with a final concentration of 50-60 g/ml.  All sample analytes were subjected to 
Electrospray Ionization (ESI) in both positive and negative modes, and were detected at 
the mass to charge (m/z) range between 100 to 700 (or 800).  Due to the abundance of 
negative ions in the molecules (i.e. phosphate ions, hydroxyl ions), only the results from 
the negative ESI mode would be presented and discussed in this thesis.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
3. RESULTS AND DISCUSSION 
 
3.1 Determination of TbMshA structure via x-ray crystallography 
 In order to determine the crystal structure of MshA from Mycobacterium 
tuberculosis (herein termed as TbMshA), a protein crystal of TbMshA was obtained via 
vapor-diffusion method under silicon oil (which promoted the slow vaporization of the 
solvent) for 12 hours up to several days.  A mountable size of the crystal (fitted in > 0.5 
Å loop) was cryo-mounted (at 120 K) and shot by a monochromatic x-ray beam; the 
scattering of x-ray by the crystal (or diffraction) was recorded by the detector (image 
plate or CCD).  The collected data was processed using macromolecular crystallography 
software HKL2000 (15).  The whole data set was indexed into the proper space group, 
integrated and scaled accordingly to generate the reflection file ready for phasing. 
 Solving the crystal structure (or generating the electron density map which in 
turn is the Fourier Transform (FT) of the structure factor) requires both the amplitude 
and phase information from the diffraction data, but the phase of the diffraction data 
cannot be measured experimentally; hence there are computational techniques to 
determine the phase.  One of the techniques to acquire phase information is known as 
molecular replacement (MR) (16). 
 MR is commonly used to calculate the initial phase from a structurally similar 
model (or known structure) in order to reconstruct the initial electron density for an 
unknown structure.  For MR, a similar structure (typically > 30% identity is required) is 
used as a search model to perform three-dimensional rotation function and subsequent 
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three-dimensional translation function in the asymmetric unit cell to find the best fit 
solution.  The rotation function uses Patterson function calculated from the search model 
and the observed data.  This approach is used in the Molrep of CCP4 (17,18), a software 
suite used here to find the MR solutions for the apo and ligand-bound TbMshA 
structures. 
 For TbMshA apo structure, the phase was obtained by taking the C-terminal 
domain of ligand-bound TbMshA as an initial search model; once the best orientation 
was found, the C-terminal domain was fixed in the model and the N-terminal domain 
was again used as a secondary search model to obtain the overall solution for the entire 
monomer.  For ligand-bound TbMshA, the phase was obtained directly by using the 
ligand-bound CgMshA (PDB code: 3c4v) as a search model.        
 
3.2 Structural characteristics of apo TbMshA 
The crystal structures of apo TbMshA is solved via x-ray crystallography to 
resolutions of 2.32 Å (Table 1) with a space group of P21212, and unit cell dimensions of 
a = 159.3 Å, b = 56.6 Å, c = 106.6 Å,  =  =  = 90o.  The phasing of apo TbMshA was 
solved by molecular replacement (MR) with the ligand-bound TbMshA structure using 
CCP4, a collaborative software for macromolecular x-ray crystallography.  There are 
two monomers (polypeptide chains) in the asymmetric unit of apo TbMshA.  The 
monomer in the tertiary structure displays a typical β/α/β Rossmann fold (GT-B fold) 
seen in other members of glycosyltransferase superfamily (19).  There are two distinct 
domains observed in the tertiary structure in which the N-terminal domain (or N-
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domain) is having eight β-strands flanked by six α-helices, whereas the C-terminal 
domain (or C-domain) is having six parallel β-strands flanked by eight α-helices (Figure 
5).   
 
Table 1. Data collection and refinement statistics for apo and ligand-bound TbMshA.  
Data collection TbMshA 
Data set Apo Ligand-bound  
Space group                      P21212                            P41212 
Unit cell dimension (Å) 
a=159.3 b=56.5 c=106.6 
===90o 
a=123.6 b=123.6 c=154 
===90o 
Completeness (%) 99.16 (39.83 - 2.32) 99.79 (30.0 - 2.89) 
I/Iσ 32.4 22.3 
Redundancy 7.3 7.6 
Refinement Statistics     
Resolution (Å) 2.32 2.89 
Rfactor (%) 21.3 20.4 
Rfree (%) 25.3 26 
Small molecules                       2 PO4 
 2 UDP, 2 GlcNAc,  
2 PO4 
Number of atoms  5999 6114 
Number of reflections (total) 41911 27149 
Unit cell volume (Å3) 9.61 * 105 2.35 * 106 
Root mean square deviations 
(rmsd)     
Bonds (Å) 0.005 0.005 
Angles (o) 0.757 1.028 
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Figure 5. Domains of the apo TbMshA.  Pink: alpha helix; yellow: beta strand; ivory: 
turns and loops.  
 
The N-domain contains a mixture of parallel and anti-parallel β-strands, whereas 
only parallel strands are observed in the C-domain.  A stretch of flexible loop is 
supposedly connecting the two domains, however, this region is highly flexible (believed 
to be the hot spot for ligand interaction), therefore the electron density is absent for this 
region in the apo structure.        
 
3.3 Structural characteristics of ligand-bound TbMshA 
The crystal structure of ligand-bound TbMshA is solved via x-ray 
crystallography to resolution of 2.89 Å (Table 1) with a space group of P41212 and unit 
cell dimensions of a = 123.6 Å, b = 123.6 Å, c = 154.0 Å,  =  =  = 90o.  The phasing 
of ligand-bound TbMshA is solved using MR with its close homologue (with a sequence 
identity of 45%) in Corynebacterium glutamicum, CgMshA (PDB code: 3c4v).  The 
asymmetric unit cell of ligand-bound TbMshA contains two polypeptide chains, with 
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each chain in its tertiary structure is displaying the same β/α/β Rossmann fold observed 
in the apo TbMshA.  The N/C domains in ligand-bound TbMshA also comprise the same 
arrangement of β-strands flanked by α-helices as observed in the apo form (Figure 5).  In 
addition, the loops that are invisible in the apo structure are become visible in the ligand-
bound structure, Figure 6, indicated by the two arrows. 
 
 
Figure 6. The C-terminal domain of the UDP-GlcNAc-bound TbMshA.  Pink: alpha 
helix; yellow: beta strand; ivory: turns and loops. 
 
The residues in the ligand-bound TbMshA structure that are interacting with the 
UDP-GlcNAc are Q331, H333, G67, L357, V358, E361, R273, K278, H178, E353, 
F355 and S354 (Figure 7).  Among these, E353 is proposed here to be critical for the 
catalysis of TbMshA, as it is in close proximity of the N-acetyl-glucosamine moiety 
(believed to be transferred onto the acceptor substrate).    
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Figure 7. A schematic drawing of UDP-GlcNAc interacting with surrounding residues.  
Figure is prepared using ChemBioDraw Ultra 11.0. 
  
3.4 Ligand-bound TbMshA reveals a C-domain movement 
The asymmetric unit reveals the apo and ligand-bound TbMshA are two 
monomers in the crystallographic packing, and gel filtration chromatography (data not 
shown) confirms that TbMshA is monomeric in solution and is the functionally active 
form (20).  Although the apo and ligand-bound TbMshA exhibit similar overall 
structure, the interface between the two monomers and the interdomain gap in the apo 
form is more open than the ligand-bound form.  In addition, the loop region in which it 
connects the N/C domains is missing in the apo structure (Figure 8).   
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Figure 8. Overall structure of apo (a) and ligand-bound (b) TbMshA in ribbons.  Red: 
alpha helices; yellow: beta strands; black: loops and turns.  Red arrows indicate the loop 
region that is missing in the apo TbMshA structure. 
 
The two domains in the closed from are facilitated by several highly flexible 
loops that are not properly shown in the absence of ligand (and thus lack electron 
densities for model building, Figure 8a).  The flexible loops are constituted by domain 
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interface residues such as, Pro-60 to Gly-66, Asn-185 to Glu-195, and Gly-299 to Ala-
308.  These loops are being stabilized upon UDP-GlcNAc binding, where the ligand is 
situated in a cleft caged by the mobile loops that are not shown in the apo structure 
(Figure 9a).  A 90o rotation along either the horizontal or vertical axis (Figure 9b and 9c) 
shows the observable secondary structures movement upon ligand binding in the C-
domain, especially α7 and α12 which become α6 and α11 (see the figures on p. 15-16).    
 
 
Figure 9. Comparison of the monomeric structure of apo and ligand-bound TbMshA 
upon vertical (b) and horizontal (c) rotation.  Magenta: apo TbMshA; aqua: ligand-
bound TbMshA. 
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The N-domain of TbMshA is relatively rigid and conserved structurally, as 
compared with its structurally known homologue, CgMshA (Figure 10). 
 
 
Figure 10. Superimposition of TbMshA with CgMshA.  A. ligand-bound TbMshA 
(aqua) superimpose with ligand-bound CgMshA (yellow, PDB code: 3c4v).  B. apo 
TbMshA (magenta) superimpose with apo CgMshA (green, PDB code: 3c48). 
 
The C-terminal domain, however, undergoes some structural movement upon 
UDP-GlcNAc binding albeit such conformational shift is less drastic as the one seen in 
the case of CgMshA (Figure 10B).  This conformational shift is manifested via the 
obvious distortion of two helices (α6 and α8) in the apo TbMshA (see the figures on p. 
15-16).  The transformed loop from helix 8 becomes parts of the mobile loop region that 
serve as a closing lid to encapsulate the bound UDP-GlcNAc (Figure 9).  The nearby 
loops are not able to be visualized by electron density, rendering the inaccessibly to 
determine the extent of loop mobility.  However, such conformational change (especially 
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hinge movement/loop closing) upon ligand and/or substrate binding is a characteristic 
feature observed in members of glycosyltransferase superfamily (21). 
The observation of C-terminal domain movement upon ligand bound in TbMshA 
is not purely a crystallographic artifact due to the choice of reference.  The 
superimposition of the N- and C-terminal domain shows non-overlapping margins (see 
Appendix C on p. 54) even though both domains display similar // fold, indicating 
the shift of the secondary structure (helices) is domain specific upon ligand binds.  The 
remarkable differences are unquestionably observed in the loop regions.  
 
3.5 UDP-GlcNAc is hydrolyzed in the ligand-bound TbMshA crystal structure 
 Previous refinement assumed that the UDP-GlcNAc was intact in the ligand-
bound TbMshA structure (see Appendix A on p. 51), however, after rounds of new 
refinement, the electron density of the ligand-bound TbMshA supports the “hydrolysis” 
of UDP-GlcNAc in which the GlcNAc moiety is separate from the UDP-GlcNAc 
(Figure 11). 
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Figure 11. The electron density map of the ligand UDP-GlcNAc shown as two separate 
pieces.  The density map is a Fo-Fc map generated from COOT, contoured at 1.7 σ.  
Left: UDP, right: GlcNAc. 
 
The original proposed ligand-bound structure of TbMshA was with an intact 
UDP-GlcNAc, however, after careful inspection and many rounds of refinement, the 
intact piece was unsupported by the new refinement as the linkage between the  
phosphate of UDP and the GlcNAc moiety was always appeared as negative density 
(from the Fo-Fc map, data not shown).  So, breaking the linkage in between the UDP-
GlcNAc in new refinement runs appeared to be plausible as the negative density was 
gone and the resulted in a decrease of the R factor (a parameter that compares the overall 
agreement between the calculated model and the actual observation).  The whole ligand 
was refined as two separate pieces, after which the GlcNAc moiety seemed to undergo a 
 23 
flipping motion.  This flipping renders the GlcNAc adopts the most stable confirmation 
(chair confirmation) and is still surrounded by the same residues as depicted by the 
figure on p. 17.  The observation of this cleavage doesn’t seems to be arbitrary or due to 
hydrolysis, because UDP-GlcNAc is still remained intact in water, as confirmed by 
Electrospray Ionization experiment (see the figure on p. 39).  Only in the presence of 
enzyme and acceptor substrate would it seem to be behaving this way.  This behavior 
may also suggest that TbMshA is undergoing a bi-bi ping pong mechanism in which the 
first by-product (UDP) leaves before the uracil moiety is transferred onto the acceptor 
substrate.       
  
3.6 Ligand-bound TbMshA structure reveals probable active site 
The interactions between UDP-GlcNAc and nearby residues in the loop region 
stabilize the mobility in which it is not observed in the apo form.  Such ligand-bound 
stabilization is also a representative phenomenon exhibited by other glycosyltransferase 
members (19).  This ligand-bound stabilization somehow enables the identification of 
several critical residues involved in the probable active site cavity (see the figure on p. 
17).  The uracil moiety forms polar interactions with the amide and carbonyl backbone 
of Gln-331, as well as the side chain of Asn-59.  The imidazole ring of His-333 helps to 
mediate the carbonyl oxygen and the ribose oxygen.  The 2’, 3’-hydroxyl group on the 
ribose are interacting with Glu-361, possibly through hydrogen bonding.  The 
diphosphate groups are stabilizing by the charged residues, Arg-273, Lys-278 at the 
beginning of α6 and the amide nitrogen from the backbone of Gly-67, Leu-357 and Val-
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358 (located at the domain interface) respectively.  The refined electron density supports 
the cleavage of GlcNAc from UDP, but it does not alter the surrounding environment of 
the N-acetyl-glucosamine moiety.  In fact, this refinement allows the ribose ring to adopt 
the most stable confirmation (chair confirmation), and it is now flipped over, having its 
pyran oxygen facing away from the  phosphate of the UDP such that the pyran oxygen 
is face-to-face with the δ nitrogen of the His-178, while the acetyl amide tail is 
interacting with Glu-353 and the amide backbone of Ser-354, and a phosphate group 
(from soaking) is at close proximity (a distance of 4.0 Å) from the 2’-hydroxyl group 
(Figure 12).   
 
 
Figure 12. A schematic drawing of UDP-GlcNAc as two separate pieces with the 
surrounding residues based on the ligand-bound TbMshA structure.  Figure is prepared 
using ChemBioDraw Ultra 11.0. 
 
 25 
The 3’ and 4’-OH of GlcNAc are facing the amide nitrogen of Phe-355 and Gly-
356, interacting thru hydrogen bonding (the distances between the amide backbone to 
the hydroxyl groups are 2.64 Å and 3.17 Å respectively).  The 6’-OH is most likely 
interacting with the δ nitrogen of His-178 through hydrogen bonding.  At a distance of 
about 4 Å from the 1’-OH of the GlcNAc moiety, a phosphate (from soaking) is fitted 
into the density in the ligand-bound TbMshA structure.  This phosphate group is 
surrounded and stabilized by a group of charged residues, such as Lys-184, Lys-122, 
Thr-179, Arg-199 and Tyr-155 that form a small binding cavity in the vicinity of the 
UDP-GlcNAc binding pocket; it seems to have a long-range interaction with the 1’-
hydroxyl group of GlcNAc (Figure 13).   
 
 
Figure 13. A schematic drawing of the phosphate “pocket” with its surrounding charged 
residues, at a distance that is around 4 Å from the GlcNAc moiety.  Figure is prepared 
using ChemBioDraw Ultra 11.0. 
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Because the phosphate is about 4 Å away from the pyran oxygen of the GlcNAc 
moiety, its occupancy in the cavity may have coincided with the 1’-phosphatyl group of 
I-1-P (see Appendix A on p. 51).  This configuration would have been enabled the sugar 
moiety of I-1-P in a direct face-to-face interaction with the sugar moiety of the UDP-
GlcNAc, whose sugar moiety has been considered as the responsible sugar donor that is 
transferred onto the substrate (20).  However, because there is no crystallographic 
evidence to show where I-1-P binds in the ligand-bound TbMshA structure (due to 
failure in obtaining crystals in this regard), the mode of action for the GlcNAc transfer 
remains speculative for TbMshA at this point.   
 
3.7 E353 may be the nucleophile for catalysis in TbMshA 
Based on the crystal structure of the ligand-bound TbMshA, Glu-353 is in the 
proximity of the  phosphate of UDP and the pyran oxygen of the GlcNAc moiety (see 
the figure on p. 24).  More importantly, this residue can serve as a nucleophile in the 
protein crystal (given the pKa for glutamate side chain is 4.1 and the pH of the crystal 
condition is 8.5).  In the previous refined structure (data not shown), there was an 
ordered water molecule (within hydrogen bonding distance) in the proximity of Glu-353.  
Therefore, it was proposed to increase the nucleophilicity of a water to attack the C1’ 
position of the pyran.  However, in the re-refined structure of ligand-bound TbMshA, 
this ordered water is not seen anymore and the UDP-GlcNAc is shown as pieces.  One 
may speculate that the splitting of UDP-GlcNAc may due to its high hydrolytic profile in 
solution.  But, mass spectrometry indicates that UDP by itself is not observed in the 
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spectrum in aqueous solution, indicating that UDP-GlcNAc is not hydrolyzed easily in 
solution (see the figure on p. 39).  But interestingly enough, UDP-GlcNAc is not 
hydrolyzed either into UDP and GlcNAc in only the presence of the enzyme without the 
acceptor substrate (see the figure on p. 41).  Hence, even if one wishes to propose the 
mechanism is bi-bi ping pong, the intermediate product is not readily released until the 
acceptor substrate has come in.  However, in this case, phosphate was used during 
crystallization to mimic the presence of the I-1-P, then the split UDP-GlcNAc was 
observed.  Although the attempt to co-crystallize with both substrates (UDP-GlcNAc 
and I-1-P) had failed to produce diffraction-quality crystals for data collection, based on 
the tertiary complex obtained from the pieces of UDP-GlcNAc and phosphate, as well as 
the known structural information from a close homologue (CgMshA), a mechanism is 
proposed (Figure 14).  Glu-353 located around 4 Å from the anomeric carbon of the 
GlcNAc moiety is believed to be a nucleophile to initiate the attack, making the 
electrons readily withdrawn to the oxygen in the  phosphate of UDP, while the 
diphosphate groups are charged stabilized by the nearby basic amino acids (R273 and 
K278).  The proposed intermediate state may involve a covalently bound N-acetyl-
glycosyl-enzyme intermediate to stabilize the transition state before the final attack from 
the 3’-OH of I-1-P to form the product (GlcNAc-Ins-P).  Since there is no direct 
crystallographic evidence to support this mechanism, a composite figure (see Appendix 
A on p. 51) from ligand-bound TbMshA and CgMshA structure is generated using 
Chimera to illustrate the interactions that are consistent with the scheme shown in Figure 
14. 
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Figure 14. Proposed mechanism for the transfer of the glucosamine moiety onto the 
substrate I-1-P. The uracil moiety from UDP is represented as R. Figure is prepared 
using ChemBioDraw Ultra 11.0.    
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Based on the current refined ligand-bound TbMshA structure, the diphosphate 
group is stabilized by flanking charged residues (Lys-278, Arg-273, and the amide 
backbone of Gly-67, Leu-357 and Val-358), the diphosphate group is therefore ready to 
withdraw electrons, facilitating the formation of the transition state.  
The TbMshA crystal structure solved with UDP-GlcNAc cannot fully depict 
TbMshA’s sugar donor-to-acceptor mechanism, partly because the structure is solved at 
a relatively low resolution (2.89 Å).  Also, even though a pseudo substrate, myo-inositol, 
was used for soaking, no extra positive density that corresponded to the size of the 
molecule was found.  This may infer that myo-inositol is not a good substrate analogue 
for the acceptor.  Although the exact details on the transferring mechanism occurred for 
TbMshA is entirely speculative at this point, a mutation purposely introduced for 
TbMshA at residue 353 renders the mutant form (E353Q) hinders its enzyme activity 
compared to the wild-type as well as loosing the capability to produce the product (see 
Section 3.9-3.11).     
 
3.8 TbMshA vs. CgMshA 
Through sequence homology search, CgMshA, the glycosyltransferase from 
Corynebacterium glutamicum displays the greatest extent of sequence identity (~45%, 
Figure 15) and structure similarity (especially in the ligand-bound structure, see the 
figure on p. 20).   
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TbMshA             1 MAGVRHDDGSGLIAQRRPVRGEGATRSRGPSGPSNRNVSAADDPRRVALL     50 
                                                                 .|||:: 
CgMshA             1                                             MRVAMI      6 
 
TbMshA            51 AVHTSPLAQPGTGDAGGMNVYMLQSALHLARRGIEVEIFTRATASADPPV    100 
                     ::|||||.||||||:||||||:|.:|..||::||||:|:||||..:...: 
CgMshA             7 SMHTSPLQQPGTGDSGGMNVYILSTATELAKQGIEVDIYTRATRPSQGEI     56 
 
TbMshA           101 VRVAPGVLVRNVVAGPFEGLDKYDLPTQLCAFAAGVL---RAEAVHEPGY    147 
                     ||||..:.|.|:.|||:|||.|.:|||||.||..|:|   |.|.|    . 
CgMshA            57 VRVAENLRVINIAAGPYEGLSKEELPTQLAAFTGGMLSFTRREKV----T    102 
 
TbMshA           148 YDIVHSHYWLSGQVGWLARDRWAVPLVHTAHTLAAVKNAALADGDGPEPP    197 
                     ||::|||||||||||||.||.|.:||:|||||||||||:...|.|.||.. 
CgMshA           103 YDLIHSHYWLSGQVGWLLRDLWRIPLIHTAHTLAAVKNSYRDDSDTPESE    152 
 
TbMshA           198 LRTVGEQQVVDEADRLIVNTDDEARQVISLHGADPARIDVVHPGVDLDVF    247 
                     .|.:.|||:||.||.|.|||.:|.:.::..:.|||.||.||.||.|:::: 
CgMshA           153 ARRICEQQLVDNADVLAVNTQEEMQDLMHHYDADPDRISVVSPGADVELY    202 
 
TbMshA           248 RPGDRRA---ARAALGLPVDERVVAFVGRIQPLKAPDIVLRAAAKL----    290 
                     .||:.||   :|..||:|:..:|||||||:||.|.|.::::|.|.|     
CgMshA           203 SPGNDRATERSRRELGIPLHTKVVAFVGRLQPFKGPQVLIKAVAALFDRD    252 
 
TbMshA           291 --PGVRIIVAGGPSGSGLASPDGLVRLADELGISARVTFLPPQSHTDLAT    338 
                       ..:|:|:.|||||.. |:||....:|:|||:..|:.||.|:..::|.. 
CgMshA           253 PDRNLRVIICGGPSGPN-ATPDTYRHMAEELGVEKRIRFLDPRPPSELVA    301 
 
TbMshA           339 LFRAADLVAVPSYSESFGLVAVEAQACGTPVVAAAVGGLPVAVRDGITGT    388 
                     ::||||:|||||::|||||||:||||.||||:||.|||||:||.:|.||. 
CgMshA           302 VYRAADIVAVPSFNESFGLVAMEAQASGTPVIAARVGGLPIAVAEGETGL    351 
 
TbMshA           389 LVSGHEVGQWADAIDHLLRLCAGPRGRV-MSRAAARHAATFSWENTTDAL    437 
                     ||.||....||||:..||   .....|: |...|..||.||||..|...| 
CgMshA           352 LVDGHSPHAWADALATLL---DDDETRIRMGEDAVEHARTFSWAATAAQL    398 
 
TbMshA           438 LASYRRAIGEYNAERQRRGGEVISDLVAVGKPRHWTPRRGVGA           480 
                     .:.|..||...|.:.:...|              
CgMshA           399 SSLYNDAIANENVDGETHHG                   426 
 
Figure 15. Sequence alignment of TbMshA and CgMshA.  The conserved residues 
responsible for interacting with the ligand (UDP-GlcNAc) are highlighted.  “|” indicates 
identical residues.   
 
In the apo form of CgMshA (PDB code: 3c48), the C-terminal domain undergoes 
a substantial conformational change (> 90o rotation) with respect to the N-terminal 
domain.  The apo CgMshA is also more open compared to the ligand-bound CgMshA 
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(22).  The ligand-bound structure (PDB code: 3c4v) contains the electron density for 
UDP and the acceptor substrate I-1-P but not the GlcNAc moiety, which is later modeled 
in the ligand-bound structure.  Residues that are interacting with the UDP-GlcNAc in the 
CgMshA model are conserved in the TbMshA (Figure 15), except Arg-294 in CgMshA 
where it is being replaced by Gln-331 in TbMshA, which has hydrogen bond interaction 
with the 2’ amine in the uracil moiety.  Because the full length molecule of UDP-
GlcNAc is modeled in and it is not derived from the electron density in the ligand-bound 
CgMshA structure, the actual orientation of the GlcNAc moiety with respect to the UDP 
is also speculative in the case of the ligand-bound CgMshA structure.  In the ligand-
bound TbMshA structure, although the electron density for the whole molecule seems to 
be connected, the refinement result supports the hydrolysis of the bond between the UDP 
and GlcNAc moiety.  Hence, with this hydrolysis, the orientation of the GlcNAc is 180o 
flipped compared to the original proposed structure (see the figures on p. 17, p. 24 and 
Appendix A on p. 51).  In addition, this flipping over of the GlcNAc makes it possible 
for the 1’ hydroxyl group facing the phosphate pocket in a near distance (see the figure 
on p. 25).  Although still lacking substantial crystallographic evidence, this orientation in 
fact is in favor of the proposed mechanism (see the figure on p. 28).  Furthermore, a 
cavity suggested by CgMshA which consisted of a cluster of charged and polar residues 
for the acceptor substrate is also coincidentally occupied by the phosphate group in the 
TbMshA ligand-bound structure.  Whether this is actually the site that will be occupied 
by the substrate, I-1-P, is not definite (only a composite figure is generated to mimic the 
situation in crystal structure of TbMshA).  However, should the phosphate group from 
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the I-1-P occupy the same phosphate pocket as observed in the TbMshA ligand-bound 
structure, UDP should be leaving the cavity first, allowing more rooms for the other 
residues to move around, especially allowing the GlcNAc moiety to be pushed forward 
and be posed itself against the I-1-P for bonding.  If this is the case, such mechanism is 
not depending on a SNi-substrate assisted mechanism which involves an oxocarbenium-
ion like transition state, as observed in the case of CgMshA (22), but rather, it follows 
through a more classical retaining glycosyltransferase mechanism in substrate transfer as 
seen in the cases of other retaining glycosyltransferases (19,23).  
 
3.9 TbMshA enzyme assay  
To date, there are no kinetic parameters obtained directly for TbMshA, except for 
that of the closest homologue of MshA in Corynebacterium glutamicum (CgMshA) 
provided by recent literature (22).  Hence, this part of the thesis attempts to obtain the 
kinetic parameters, such as Km, Vmax, kcat and kcat/Km for TbMshA.  In addition, the 
finding of kinetic parameters would facilitate the comparison of TbMshA with its 
homologues in other Mycobacterium species, as well as to provide the preliminary data 
needed to investigate the activities of TbMshA and study its inhibition in the near future.      
Since TbMshA belongs to the glycosyltransferase superfamily, substrates of 
these superfamily members are usually donor-acceptor pairs, in which the donor is 
generally nucleotide-based sugar, and the acceptor is variable upon the catalytic 
specificity of each member.  TbMshA utilizes the UDP-GlcNAc – I-1-P donor-acceptor 
pairs, in which the GlcNAc moiety will be first hydrolyzed by the enzyme, generating 
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free UDP.  The GlcNAc moiety will then be transferred onto the acceptor, I-1-P, 
generating the first intermediate product, GlcNAc-inositol-phosphate (GlcNAc-Ins-P), 
which is the first intermediate in the mycothiol biosynthesis pathway.  The free UDP 
generated from TbMshA then becomes the substrate of another enzymes pair: pyruvate 
kinase (PK) and lactate dehydrogenase (LDH), whose reaction would oxidize the 
reducing agent NADH to NAD+; hence, the TbMshA assay is performed via a coupled 
enzyme assay fashion (23).  The spectroscopic measurement of the enzyme activity is 
feasible via the oxidation of NADH to NAD+ at 340 nm, as shown in Figure 16:   
 
 
Figure 16. A schematic representation of the coupled-enzyme reaction carried out by 
TbMshA, at the expense of oxidizing NADH to NAD+.   
 
In order to determine the basic kinetic parameter for TbMshA, the enzyme 
reaction rate with respect to the substrate concentration is measured.  Since TbMshA 
utilizes two substrates, the kinetic profile is plotted for one substrate while holding the 
other constant at saturation.  Each profile demonstrates the Michaelis-Menten kinetics 
assuming steady state (change of enzyme-substrate complex remains constant over 
time).  The Michaelis-Menten equation (Equation 1) models the kinetics such that v is 
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the reaction rate (in M sec-1) at any given substrate concentration [S] (in M), Vmax is 
the maximum velocity (in M sec-1), Km is the Michaelis-Menten constant (in M), 
which corresponds to the concentration of substrate at half Vmax.   
 
v = (Vmax [S])/(Km + [S])        (Eq.1)
  
In order to plot the reaction rate in the proper unit (M/sec), the raw data plot, 
which measures the enzyme activity by obtaining the slope of decline in absorbance at 
340 nm over time (30 minutes), is converted into the rate at which the product is formed.  
Based on Figure 16 (on p. 33), the formation of NAD+ is in 1:1 molar ratio with UDP, 
which is generated from TbMshA, hence, proper [NAD+] calibration (data not shown) 
allows one to convert the spectroscopic slope into reaction rate in micro-molar 
concentration per unit time.  Another way to figure out the Km and Vmax of the enzyme 
kinetics is to take the reciprocal of the Michaelis-Menten equation (Equation 2): 
 
1/v = (Km/Vmax) (1/[S]) + 1/Vmax       (Eq.2) 
 
The reciprocal plot or Lineweaver-Burk plot (see Appendix B-1 and B-2) allows 
determination of the Km and Vmax directly from the slope and the y-intercept.    
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3.10 WT vs. mutant (E353Q) TbMshA  
 The coupled enzyme assay is also performed in the same manner for the mutant 
TbMshA, E353Q, and its kinetic profile (following Michaelis-Menten kinetics) is plotted 
against the wild-type (Figure 17 and Figure 18) for comparison.  
 
 
Figure 17. Plot of reaction rate (in M sec-1) versus UDP-GlcNAc concentration while 
holding I-1-P constant at 2 mM.  Open circle: wild-type (WT) TbMshA; open square: 
mutant TbMshA, E353Q.  Figure is generated using KaleidaGraph 4.0. 
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Figure 18. Plot of reaction rate (in M sec-1) versus I-1-P concentration while holding 
UDP-GlcNAc constant at 4 mM.  Open circle: wild-type TbMshA; open square: mutant 
TbMshA, E353Q.  Figure is generated using KaleidaGraph 4.0. 
 
 The activity of the mutant is significantly quenched compared to the wild-type.  
The apparent maximum velocity, Vmax, is reduced by more than four-fold in the mutant 
form (Table 2).  The values of Km and Vmax can be directly obtained from the 
Lineweaver-Burk plot, and kcat , the turnover number of an enzyme, is calculated from 
Vmax divided by the total concentration of enzyme, [E]T, such that (Equation 3): 
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kcat = Vmax/[E]T ≈ Vmax/[E]                   (Eq.3) 
 
The total enzyme concentration [E]T in the reaction is the sum of enzyme-
substrate complex concentration [ES] and free enzyme concentration [E], but assuming 
steady state, [ES] does not change over time (because it returns to free enzyme as soon 
as product forms), then [E]T is approximately equal to [E], which is 0.2 M in this case. 
 Based on the kinetics data, the Michaelis-Menten constants (Km) for UDP-
GlcNAc and I-1-P are found to be 210 M and 331 M respectively.  The Km found for 
the mutant, E353Q, is 204 M for UDP-GlcNAc, 113 M for I-1-P.  The Vmax for wild-
type TbMshA is found to be 0.17 ± 0.02 M sec-1, which is four-fold higher than that for 
E353Q (0.04 ± 0.01 M sec-1).  The turnover number, kcat, is 0.9 ± 0.1 sec-1 for wild-
type, and 0.2 ± 0.1 sec-1 for E353Q.  kcat/Km, which provides an index of enzymatic 
catalytic efficiency, is calculated to be 3.5 ± 1.1 * 103 M-1 sec-1 for the wild-type 
TbMshA and 0.3 ± 0.02 * 103 M-1 sec-1 for the mutant.  Table 2 summarizes the kinetic 
parameters found for the wild-type and mutant TbMshA: 
 
Table 2. Kinetic parameters for WT and mutant (E353Q) TbMshA. 
TbMshA Km, M       
  
UDP-
GlcNAc I-1-P Vmax, M sec
-1 
kcat, sec
-1
 kcat/Km, M
-1
 sec
-1
 
WT 210 331  0.17 ± 0.02  0.9 ± 0.1  3.5 ± 1.1 * 103 
E353Q 204 113  0.04 ± 0.01  0.2 ± 0.1  0.3 ± 0.1 * 103 
 
 38 
 The kinetic parameters reveal that the mutant has displayed a greatly reduced 
enzyme activity.  The Vmax for E353Q are four-fold lower than that of the wild-type, and 
the kcat of E353Q is even an order of magnitude lower compared to that of the wild-type.  
Although the Km for UDP-GlcNAc for both enzymes is comparable, since the mutant has 
a greatly reduced kcat, the catalytic efficiency (kcat/Km) of the mutant is still about four-
fold lower than that of the wild-type, indicating that the mutation at residue 353 is 
indeed impairing the native enzyme activity. 
 
3.11 Mass spectrometry analysis of TbMshA 
Since the coupled enzyme assay could only detect the liberation of UDP to 
demonstrate the activity of TbMshA, there is actually no definite answer as to whether 
TbMshA would get to make the product in the reaction.  In this regard, there is a need to 
find out whether both wild-type and mutant form of TbMshA can make product, even 
though the enzyme activity of the mutant is greatly hindered.  In vitro reaction products 
of wild-type TbMshA and its mutant form, E353Q, are subject to Electrospray Ionization 
(ESI, negative mode) to trace the presence of the immediate product, GlcNAc-Ins-P.  
The results indicate that wild-type TbMshA is able to produce GlcNAc-Ins-P 
(C14H25NO14P, with a negative charge, which has an m/z of 462).  But this product is not 
observed in the case of the mutant, E353Q, since there is no corresponding peak at this 
m/z value.  The controls used in this ESI experiment are the two substrates, UDP-
GlcNAc (C17H27N3O17P2 , Mw = 607 g/mol, m/z = 302.5), and I-1-P (C6H11O9P2,  Mw = 
259 g/mol, m/z = 259.1) (Figure 19).    
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 A)                                                      
 
 
 
B) 
 
 
Figure 19. ESI spectra (negative mode) of A) UDP-GlcNAc, B) I-1-P, C) WT TbMshA, 
and D) mutant form of TbMshA, E353Q. 
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C) 
 
 
 
D) 
 
 
Figure 19 continued. 
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The wild-type TbMshA shows a peak corresponds to the mass of its immediate 
product, GlcNAc-Ins-P, at 462 m/z (assuming a unit charge), while in the ESI profile of 
the mutant form, E353Q, this peak is absent, indicating that the E353Q cannot turn over 
the substrates.  In the kinetic assay, TbMshA is believed to first release the UDP from 
UDP-GlcNAc before the GlcNAc moiety is transferred onto I-1-P.  This “release first” 
mechanism is supported by the crystal structure of ligand-bound TbMshA, however, this 
hypothesis is not fully supported because the ESI results still show an “intact” molecule 
of UDP-GlcNAc (no peak corresponds to free UDP) when the reaction mixture only 
contains UDP-GlcNAc and enzyme without the acceptor substrate, I-1-P (Figure 20).  
 
    
 
Figure 20. ESI spectrum of UDP-GlcNAc with TbMshA only. 
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This spectrum looks similar to the control in which it only has UDP-GlcNAc 
(dissolved in water), the noisy peaks at the background, as well as the sharp peak 
observed at 127 m/z for all the spectra are believed to be the fragments from the HEPES 
buffer (where the in vitro reactions were taken place).  However, this spectrum cannot 
fully dispute the fact that UDP can be first hydrolyzed before transfer because the 
sample analyte was prepared by precipitating the protein (since some amount of ligand 
may be attached to the precipitating protein).  A better approach to obtain the analyte 
could be to extract the solution form of the ligand from the ligand-bound TbMshA 
crystal directly to get a more definite and consistent results with the crystallographic 
data, unfortunately, this approach was unable to be followed in time. 
 
3.12 The reaction sequence of UDP and I-1-P  
Based on the ligand-bound TbMshA structure, UDP-GlcNAc is split into two 
separate pieces – UDP and GlcNAc (refinement supports this), in which they are 
securely stabilized by the neighboring residues in the structure (see the figure on p. 24).  
It is the liberation of UDP allows one to measure the enzyme activity of TbMshA using 
a coupled enzyme assay method, which is most commonly used for glycosyltransferase 
besides the traditional radio-labeling techniques (19,24).  However, what is the reaction 
sequence of the donor-acceptor pair?  The answer to this question is not clearly defined 
by the crystallographic structure alone.  In the in-vitro reaction where UDP-GlcNAc is 
only with TbMshA, no detection of free UDP at all (see the figure on p. 41), and UDP is 
indeed present in the crystal structure but is not leaving yet (still in the active site 
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pocket).  Previous experiments (data not shown) have had performed for TbMshA with 
only UDP-GlcNAc but not I-1-P showed a decreased slope but with less decline.  It may 
indicate trace amount of UDP is releasing into the solution over time (the enzyme 
reaction was monitored over a period of 30 minutes).  But, in the presence of I-1-P, the 
slope declines much faster (data not shown).  The entry of acceptor seems to facilitate 
the leaving of UDP as one would predict from the crystal structure that there needs more 
room for the sugar transfer to take place.  
 
3.13 E353Q impairs TbMshA activity and hinders product formation 
The ligand-bound TbMshA structure shows Glu-353 is at a strategic spatial 
location, in which it is seemed to be mediating the interaction with UDP-GlcNAc.  More 
importantly, as UDP-GlcNAc has split into two pieces (supported by the refinement, see 
the figure on p. 22), Glu-353 is still taking the spatial advantage over other nearby 
residues because it now becomes the “middle-man” of UDP and GlcNAc (see the figure 
on p. 24), allowing one to speculate its role as a true nucleophile in the catalysis.  The 
mechanism proposed here (see the figure on p. 28) relies on the hypothesis that Glu-353 
is serving as a nucleophile to initiate the attack to cleave the UDP-GlcNAc bond.  Glu-
353 uses its carboxyl (R-COO-) to attack on the C1’ of the pyran ring of GlcNAc, 
allowing diphosphate to dissociate readily.  The mutation of Glu-353 is simply a single-
point mutation, in which the glutamate is mutated to glutamine through site-directed 
mutagenesis.  Glutamate and glutamine are quite indistinguishable structurally because 
there’s only one functional group difference (carboxylic group is changed to an amine 
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(R-CONH2)).  If this carboxyl is the source of generating the nucleophile to initiate the 
attack, when the functional group is changed to amine, this source is completely blocked 
because amine (-NH2) is less basic compared to glutamate, especially when the pH is at 
physiological range (pH 8.0).  The weakening of the mutant TbMshA in its enzyme 
activity as well as the inability to produce its immediate product demonstrate that 
E353Q, after the glutamate is mutated to glutamine, is unable to serve as a nucleophile to 
facilitate the downstream reaction.  
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4. CONCLUSIONS 
 
The structure of the precursor enzyme, MshA, in the mycothiol biosynthesis 
pathway in Mtb, is solved via x-ray crystallography to a resolution of 2.32 Å.  The 
structure of the enzyme complexed with a ligand (UDP-GlcNAc) that is known to be the 
donor substrate is also solved using the same crystallographic technique, to a lesser 
resolution of 2.89 Å.  Both structures form two monomers in the asymmetric unit with 
distinctive N- and C- terminal domains that are connected via a stretch of flexible loop, 
although such loop region is absent in the apo TbMshA structure.  The tertiary structure 
of the monomer shows the MshA in Mtb is following a typical β/α/β Rossmann fold 
(GT-B fold) as seen in other retaining glycosyltransferase superfamily members.  
Compared to the ligand-bound structure, the apo structure of TbMshA is more open 
between the N- and C-terminal domain, leaving the connection loops between domains 
more mobile (thus higher disorderness in this region), however, this gap also opens the 
door to accept substrates.  Once the substrate (or ligand) is bound, this gap somehow 
“closes up” in between the domains and be stabilized by the interactions with the ligand.  
This phenomenon is also observed in TbMshA’s closest homologue in Corynebacterium 
glutamicum (CgMshA), however, the apo form of TbMshA has its C-terminal domain 
extend in lesser degree than that of CgMshA while the N-terminal domains in both 
structures stay rigid. 
Ligand-bound TbMshA enables the visualization of several critical residues that 
are interacting with UDP-GlcNAc.  Although based on the refinement of UDP-GlcNAc, 
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whose electron density supports the fragmentation into UDP and GlcNAc, the two 
fragments are still intact in its local interaction, except with GlcNAc moiety flipped 
180o, adopting its most favorable chair confirmation.  Either the soaking or co-
crystallization of the second substrate, I-1-P, to TbMshA tertiary complex is not 
successful, hence, no direct inference of mechanism can be drawn from the structure.  
However, the ligand-bound TbMshA crystal structure contains refined phosphate (which 
was the result from soaking as well), and the occupancy of this phosphate is in direct 
facing to the 1’-OH of GlcNAc, which indicates that this phosphate binding pocket 
maybe the cavity in which I-1-P will bind should it enter to the structure.  Based on the 
location of residues that are in direct interactions with the UDP, GlcNAc and PO4, a 
mechanism is drawn to illustrate the plausible sugar transfer.  In addition, a critical 
residue, Glu-353, is indentified to be a nucleophile responsible for TbMshA catalysis.  
The kinetics assays were carried out for both the wild-type and the mutant form 
(E353Q) of TbMshA.  The Km for wild-type TbMshA for UDP-GlcNAc and I-1-P are 
found to be 210 M and 331 M, respectively.  The Km for the mutant E353Q for UDP-
GlcNAc and I-1-P are found to be 204 M and 113 M, respectively.  The kcat for the 
reaction catalyzed by wild-type TbMshA is calculated to be 0.17 ± 0.02 sec-1, whereas 
for the mutant it is 0.04 ± 0.01 sec-1, indicating the enzyme activity is greatly hampered 
by the mutant by at least 4-fold.  kcat/Km for wild-type TbMshA is 3.5 ± 1.1 * 103 M-1 
sec-1, about ten times higher than that of the mutant, which has a kcat/Km of only 0.3 ± 0.1 
* 103 M-1 sec-1.  In addition, mass spectrometry analysis through Electrospray Ionization 
(ESI) experiments show that the mutant is incapable of making the immediate product 
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(GlcNAc-Ins-P).  Both the kinetic and mass spectrometry data support the hypothesis 
that mutation in Glu-353 causes the enzyme losing activity as well as preventing the 
formation of the product, thus, inhibiting the transfer reaction.   
The findings here show that Glu-353 is needed for catalysis, and mutation to 
glutamine, which is structurally similar but functionally different, weakens the enzyme’s 
activity and impede the transfer reaction (i.e. product formation).  The major functional 
group of glutamate is the carboxylic group, which can serves as a nucleophile to activate 
the reaction whereas an amine group fails to do the same job in this case.     
This thesis attempts to present a structural and functional analysis of the 
precursor enzyme, MshA, in the mycothiol biosynthesis pathway in Mtb.  While the cure 
of TB remains as challenging as the eradication of Mtb, much more research work is 
needed to target this pathogen’s own survival gear in the near future.  
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APPENDIX A 
 
A)                   B) 
 
 
A composite figure generated by Chimera. Cyan: unhydrolyzed UDP-GlcNAc in 
TbMshA structure (previously refined); magenta: UDP in CgMshA structure (PDB code: 
3c4v); white: hydrolyzed UDP-GlcNAc in TbMshA (current refinement).  The UDP and 
PO4 of TbMshA overlap with that of CgMshA.    
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APPENDIX B-1 
 
  
 53 
APPENDIX B-2 
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APPENDIX C 
 
 
 
Overlay of the N-domain (N-terminal to Pro-240, colored yellow) and C-domain (Gly-
241 to C-terminal, colored orange red) for the apo and ligand-bound TbMshA structures 
with 90 degree of horizontal rotation shown at the bottom portion. 
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